Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
复制标题
DOI：
10.1002/mds.27038
复制
发表时间：
2017-07
期刊：
影响因子：
--
通讯作者：
Movement Disorder Society-endorsed PSP Study Group
中科院分区：
文献类型：
--
作者：
Whitwell JL;Höglinger GU;Antonini A;Bordelon Y;Boxer AL;Colosimo C;van Eimeren T;Golbe LI;Kassubek J;Kurz C;Litvan I;Pantelyat A;Rabinovici G;Respondek G;Rominger A;Rowe JB;Stamelou M;Josephs KA;Movement Disorder Society-endorsed PSP Study Group
PSP是一种病理学定义的神经退行性tau蛋白病，具有多种临床表现，包括典型的Richardson综合征和其他变异的PSP综合征。在过去的二十年里，人们进行了大量的神经影像学研究，许多研究提出了PSP的不同结构MRI和分子PET/SPECT生物标志物。这些措施包括脑干，皮质和纹状体萎缩，扩散加权和扩散张量成像异常，[18 F]氟脱氧葡萄糖PET代谢低下，纹状体多巴胺成像减少，最近，PET成像与tau蛋白结合的配体。我们的目的是严格评估结构和分子神经影像学指标满足PSP诊断生物标志物标准的程度。我们在PubMed、科克伦、Medline和PSYCInfo数据库中查询了1996年至2016年使用死后诊断或NINDS-SPSP标准作为诊断标准的过去20年中以英文发表的原始研究文章。我们定义了一个五个级别的理论结构，用于神经影像学生物标志物在PSP中的效用，1级代表组水平的发现，2级代表具有可证明的个体水平诊断效用的生物标志物，3级代表早期疾病的生物标志物，4级代表PSP病理学的替代生物标志物，5级代表PSP病理学的确定性PSP生物标志物。我们讨论了目前可用的生物标志物在多大程度上适合这个理论结构，考虑生物标志物在Richardson综合征，变异PSP综合征和尸检证实的PSP诊断中的作用，并强调目前在该领域的不足。
PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau. Our aim was to critically evaluate the degree to which structural and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English over the past 20 years using postmortem diagnosis or the NINDS-SPSP criteria as the diagnostic standard from 1996 to 2016. We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology. We discuss the degree to which each of the currently available biomarkers fit into this theoretical construct, consider the role of biomarkers in the diagnosis of Richardson's syndrome, variant PSP syndromes and autopsy confirmed PSP, and emphasize current shortfalls in the field.
登录
查看更多内容
影响因子：
3.8
作者：
Abe, K;Terakawa, H;Yanagihara, T
通讯作者：
Yanagihara, T
影响因子：
6
作者：
Agosta, Federica;Galantucci, Sebastiano;Filippi, Massimo
通讯作者：
Filippi, Massimo
影响因子：
8.6
作者：
Coon, Elizabeth A.;Whitwell, Jennifer L.;Josephs, Keith A.
通讯作者：
Josephs, Keith A.
影响因子：
4.1
作者：
Botha, Hugo;Whitwell, Jennifer L.;Josephs, Keith A.
通讯作者：
Josephs, Keith A.
影响因子：
--
作者：
Boxer, AL;Geschwind, MD;Rosen, HJ
通讯作者：
Rosen, HJ